In Vitro Diagnostics
This article was originally published in SRA
US approves two first-of-a-kind in vitro diagnostics
You may also be interested in...
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
Integra is divesting its underperforming extremity orthopedics product portfolio to focus on its neurosurgery, surgical instrument and regenerative medicine businesses.